BiotechTube

Cinacalcet + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Hyperparathyroidism

Conditions

Secondary Hyperparathyroidism, Chronic Kidney Disease

Trial Timeline

Aug 22, 2006 → Apr 10, 2012

NCT ID
NCT00345839

About Cinacalcet + Placebo

Cinacalcet + Placebo is a phase 3 stage product being developed by Amgen for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT00345839. Target conditions include Secondary Hyperparathyroidism, Chronic Kidney Disease.

What happened to similar drugs?

13 of 20 similar drugs in Secondary Hyperparathyroidism were approved

Approved (13) Terminated (0) Active (7)
✅Cinacalcet HClKyowa KirinApproved
✅Paricalcitol + CalcifediolAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved
✅RanibizumabNovartisApproved
✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
✅RanibizumabNovartisApproved
✅Sensipar® + Vitamin DAmgenApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT01250405ApprovedCompleted
NCT00975221Phase 3Completed
NCT00975000Phase 3Completed
NCT00345839Phase 3Completed
NCT03776058Phase 2Completed
NCT03774771Phase 2Completed

Competing Products

20 competing products in Secondary Hyperparathyroidism

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
FycompaEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38
KHK7580Kyowa KirinPhase 1
29
KHK7580Kyowa KirinPhase 3
40
KHK7580Kyowa KirinPhase 3
40
Cinacalcet HClKyowa KirinApproved
43
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
35
dirucotide + PlaceboEli LillyPhase 2/3
38
dirucotideEli LillyPhase 2/3
30
Paricalcitol + CalcitriolAbbViePre-clinical
18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
40
Paricalcitol + CalcifediolAbbVieApproved
43
Paricalcitol + Darbepoetin alfaAbbVieApproved
43
Birabresib Dose 20 mgMerckPhase 1
21
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
47
RanibizumabNovartisApproved
43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
43